Ovarian Cancer Diagnosis
Ovarian Cancer Diagnosis
Ovarian cancer is diagnosed in two movements: imaging and markers raise the suspicion and map the disease, and surgery — in fit women with operable disease — delivers both the tissue diagnosis and the FIGO stage in the same operation.
Ultrasound: the first test
Pelvic and transvaginal ultrasound is where almost every ovarian evaluation begins, and it answers the questions that decide what happens next: is there a mass, is it ovarian, and what does it look like? Modern ultrasound characterises a mass by its internal architecture — simple cyst, complex mass with solid areas, septations, blood-flow pattern — and simple cysts in menstruating women are common findings that need no surgery.
What ultrasound cannot do is stage the disease: it sees the ovary well and the upper abdomen poorly. Its role is to decide whether the mass is worth a CT — and, together with CA-125, whether the patient should be referred to a gynaecological oncology centre rather than a general surgical service, a step that measurably changes how complete the eventual operation is.
CA-125 and HE4: what they can do
CA-125 is a blood protein that rises in many ovarian cancers — and in many benign conditions. Its honest job description: in a woman with a known mass, a high CA-125 raises suspicion and supports referral to an oncology centre; in a woman without a mass, it diagnoses nothing. After treatment it becomes a trend to follow. HE4, often paired with CA-125 in a combined score (ROMA), adds a little discrimination between benign and malignant masses.
Two usage errors to avoid. First, a normal CA-125 does not exclude ovarian cancer — a proportion of early and clear cell tumours do not raise it. Second, an elevated CA-125 without a mass is a prompt for imaging and follow-up, not for a cancer diagnosis. The marker is part of a judgement; it is not the judgement.
CT and the resectability map
CT of chest, abdomen and pelvis is the staging map. It answers two distinct questions. The first is spread: peritoneal deposits, omental cake, lymph nodes, pleural effusion, liver or spleen involvement. The second — the one that shapes the whole pathway — is resectability: whether the disease visible on CT is the kind a surgeon can remove completely in one operation. Diffuse small-bowel surface disease, disease at the root of the mesentery, or extensive diaphragmatic involvement argue that surgery should follow chemotherapy rather than precede it.
This resectability assessment is a joint reading by imaging and surgery, and it is worth doing before travel rather than after: it is the finding that decides whether a patient arrives for an operation or for chemotherapy. MRI is occasionally used for characterising an indeterminate mass; PET-CT adds information in recurrence rather than in primary staging.
Surgical staging
FIGO staging in ovarian cancer is surgical by design: the stage is assigned from peritoneal washings, biopsies of the peritoneal surfaces, omentectomy, lymph node sampling and the histology of what is removed. Scans miss deposits smaller than a centimetre; the operation does not. For a woman whose imaging suggests operable disease, the first operation is both the biopsy and the staging procedure — which is why it is planned as a cancer operation from the start, by a gynaecological oncology team, and not begun as a simple cyst removal that turns into something larger.
Where disease is clearly not resectable, or the patient is not fit, the sequence inverts: tissue is obtained by biopsy, chemotherapy starts, and surgery follows as interval debulking. Both routes end with the same information; the order is chosen to protect the completeness of the operation.
Histology and the type
The pathology report does two jobs. It assigns the type — high-grade serous, clear cell, endometrioid, mucinous, germ cell, stromal — which sets the protocol. And it grades the behaviour: high-grade serous and low-grade serous are different diseases with different chemotherapy sensitivity despite similar names. Immunohistochemistry and molecular tests on the specimen complete the picture, and the BRCA/HRD status is tested on this tissue.
For international patients the practical translation: the pathology report and, where possible, the paraffin blocks are among the most valuable items in any file sent abroad — the type decides the protocol, and the blocks allow BRCA and HRD testing without a repeat procedure.
Bringing it into one plan
Diagnosis in this disease is not complete until four documents exist: the ultrasound and CT reports with the imaging itself, the CA-125 (and HE4) values, the pathology or cytology report where tissue has been obtained, and the resectability assessment derived from the CT. The plan then answers, in order: is this operable upfront, or does chemotherapy come first; which protocol fits the type; and has germline BRCA testing been arranged.
For international patients, the file that allows a gynaecological oncology MDT to answer within 48 hours is exactly those four items. The most commonly missing is the imaging itself — discs or links rather than reports — and it is the item on which the surgery-versus-chemotherapy decision turns.